DIRS.INFO The most relevant business & tech news

☆ European regulator recommends Pfizer's Omicron booster for children
▼ + stars: | 2022-11-10 | by ( ) www.reuters.com time to read: 1 min

Nov 10 (Reuters) - Pfizer Inc (PFE.N) and its partner BioNTech said on Thursday the EU health regulator has recommended authorising the use of their bivalent COVID-19 shot as a booster in children aged 5 through 11. The Omicron-tailored vaccine is already authorised by the European Commission for individuals aged 12 years and above. The updated bivalent booster shot targets the original coronavirus strain as well as the BA.4 and BA.5 sub-variants of Omicron. In October, European Medical Agency backed authorization of Moderna Inc's (MRNA.O) COVID-19 tailored booster shots for 12 and above to further vaccination campaigns in the region. Reporting by Bhanvi Satija and Khushi Mandowara in Bengaluru; Editing by Shounak Dasgupta amd Shinjini GanguliOur Standards: The Thomson Reuters Trust Principles.

☆ Thanksgiving is two weeks away. Get your updated Covid-19 shot now, health officials warn
▼ + stars: | 2022-11-10 | by ( Jacqueline Howard | ) edition.cnn.com time to read: +8 min

CNN —With Thanksgiving just two weeks away, people who are eligible for an updated Covid-19 vaccine booster but still haven’t received the shot will need to roll up their sleeves Thursday to get as much protection as possible before the holiday. After getting the updated Covid-19 vaccine, that biological process can take about 10 to 14 days. Health officials say it’s fine to get the updated Covid-19 booster and flu vaccine at the same time. The vaccine candidate contains components of the companies’ updated Covid-19 booster and their investigational flu vaccine. Moderna is also developing a combined flu and Covid-19 mRNA vaccine and another combination vaccine targeting flu, Covid-19 and RSV.

☆ UK approves Pfizer-BioNTech's COVID booster targeting BA.4/5
▼ + stars: | 2022-11-09 | by ( ) www.reuters.com time to read: +1 min

Nov 9 (Reuters) - Britain's health regulator on Wednesday approved a COVID-19 booster from Pfizer Inc (PFE.N) and partner BioNTech SE (22UAy.DE) targeting the Omicron BA.4 and BA.5 sub-variants and the original coronavirus strain. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) said the vaccine was approved for use as a booster dose in people aged 12 years and older after it was found to meet safety, quality and effectiveness standards. "All approved COVID booster vaccines help to improve the protection obtained from earlier doses of the vaccine and help give longer-term protection against getting seriously ill from COVID-19," according to the MHRA. Pfizer and BioNTech last week said their so-called bivalent COVID-19 vaccine tailored for BA.4/5 produced a strong antibody response in older adults than the original shot after one month, and in October said it generated a strong immune response. Reporting by Pushkala Aripaka in Bengaluru; Editing by Shinjini Ganguli and Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles.

☆ We're increasing price targets on 3 of our stocks, including 2 crushing the boarder market
▼ + stars: | 2022-11-08 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Following our price target changes on eight Club holdings last month, we're updating three more Tuesday to reflect their recent quarterly earnings reports and outlooks. It's also worth noting that we have not adjusted our Lilly price target since competitor Biogen (BIIB) reported positive topline results from a study to treat early Alzheimer's. Halliburton (HAL): Club price target increasing to $44 per share from $40 This update comes about two weeks after the oilfield services provider reported a stronger-than-expected third quarter . THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

☆ BioNTech executive says it is too early to predict China vaccine approval
▼ + stars: | 2022-11-07 | by ( ) www.reuters.com time to read: +1 min

FRANKFURT, Nov 7 (Reuters) - A BioNTech (22UAy.DE) executive on Monday confirmed that the company is in discussions with Chinese authorities over regulatory approval of the German biotech firm's COVID-19 vaccine for use by expatriates in China but the outcome was uncertain. We confirm that we have been taking part in some discussions, which are very positive," Chief Strategy Officer Ryan Richardson said in an analyst call. He added it was too early to predict the extent or the timing of such an approval for foreigners working in China. BioNTech shares rose on Friday after German Chancellor Olaf Scholz announced an agreement to let expatriates in China use the vaccine and he pressed for Beijing to allow the shot to be made freely available to Chinese citizens. Reporting by Ludwig Burger, editing by Kirsti KnolleOur Standards: The Thomson Reuters Trust Principles.

☆ BioNTech lifts lower end of vaccine sales target range
▼ + stars: | 2022-11-07 | by ( ) www.reuters.com time to read: +1 min

FRANKFURT, Nov 7 (Reuters) - COVID-19 vaccine maker BioNTech (22UAy.DE) on Monday raised the lower bound of its 2022 COVID-19 vaccine revenue guidance for the full year, citing demand for its adapted shots and higher prices. The German biotech firm, the vaccines partner of U.S. pharma giant Pfizer (PFE.N), said in a statement that it is now targeting 16 to 17 billion euros ($16-$17 billion) in vaccine sales, compared with a previous range of 13-17 billion but down from 19 billion euros reported for last year. Partner Pfizer last week raised its forecast for its 2022 sales of the COVID-19 vaccine by $2 billion to $34 billion. Sales during the July-to-September quarter dropped 43% to 3.46 billion euros while net profit fell 44% to 1.78 billion euros. Sales of the Pfizer/BioNTech COVID vaccine are down from pandemic highs as many countries have neared the end of their primary vaccination campaigns.

☆ Stocks making the biggest moves in the premarket: BioNTech, Meta, Apple, Ouster and more
▼ + stars: | 2022-11-07 | by ( Peter Schacknow | ) www.cnbc.com time to read: +2 min

Berkshire Hathaway (BRK.b) – Berkshire Hathaway gained 1.5% in premarket trading after Warren Buffett's firm reported better-than-expected earnings, with revenue also topping Street forecasts. Meta Platforms (META) – Meta added 2.6% in the premarket after The Wall Street Journal reported that the Facebook parent was preparing to announce large-scale layoffs this week. Apple (AAPL) – Apple shares slid 1.8% in the premarket after it said Covid-19 restrictions are hindering iPhone production at the Foxconn factory in China. Yamana Gold (AUY) – Yamana Gold lost 2.7% in the premarket after Gold Fields (GFI) said it would not change the terms of its takeover deal with Yamana. Ryanair (RYAAY) – The airline's stock gained 6.2% in premarket trading after it reported its largest-ever profit for the first half of the year.

☆ Investors, you can bet on midterms bringing in a market rally even as the Fed keeps hiking rates.
▼ + stars: | 2022-11-07 | by ( Phil Rosen | ) www.businessinsider.com time to read: +5 min

Let's start with a basic fact: Stocks have gained after every midterm election since World War II. But Ryan Detrick, chief market strategist at Carson Group, still thinks the stage is set for a substantial year-end market rally. How do you expect the stock market to react to the 2022 midterms? US stocks are ticking higher early Monday as election week begins. It's possible the stock market crashes 29% if a drop in corporate earnings happens at the same time as a recession.

☆ Analysis: For China's COVID policy, change comes in small increments
▼ + stars: | 2022-11-06 | by ( Tony Munroe | ) www.reuters.com time to read: +6 min

Authorities are making changes such as more precisely targeting lockdowns, rolling out new vaccines and adding international flights. Daily infections, though extremely low by international standards, are hitting six-month highs, while officials repeatedly reaffirm the zero-COVID policy that President Xi Jinping argues saves lives. Still, Huang does not expect fundamental change in China's COVID policy anytime soon. "COVID is not scary, it is preventable and treatable," the city's health authority told residents. China recently began rolling out what is believed to be the world's first inhalable COVID vaccine, which could help in reducing vaccine hesitancy that is especially widespread among older Chinese.

☆ Stocks week ahead: How the midterms could affect Wall Street
▼ + stars: | 2022-11-06 | by ( Paul R. La Monica | ) edition.cnn.com time to read: +8 min

Investors are more than happy when politicians bicker but don’t actually enact any new laws that may hurt corporate profits. If Republicans get the House, tax hikes are dead in the water,” said David Wagner, a portfolio manager with Aptus Capital Advisors. That’s because there are some areas of consensus for the White House and Republican lawmakers. Congress and the White House may spend more time bickering than trying to pass legislation. Ameriprise chief market strategist Anthony Saglimbene said on a conference call last week about the midterms that stocks have historically gone up after elections, no matter which party controls the White House and Congress.

☆ His COVID lockdowns made him one of the most unpopular politicians in China. Xi Jinping just made him the 2nd-most powerful man in the country. Meet Li Qiang.
▼ + stars: | 2022-11-05 | by ( Matthew Loh | ) www.businessinsider.com time to read: +7 min

They key to his success is his loyalty to President Xi Jinping, experts say. But on October 23, Chinese President Xi Jinping made it clear: It didn't matter. Xi Jinping, Li Qiang, and other members of China's new top leadership walk in order of their rank. But his real value to Xi comes in the form of his loyalty to Xi, Wu said. Xi Jinping doesn't look into other things.

☆ First Russia, now China? Europe doesn’t appear ready to ‘decouple’ from Beijing just yet
▼ + stars: | 2022-11-04 | by ( Marie Brockling | ) www.nbcnews.com time to read: +8 min

Scholz was the first leader of a Group of 7 nations to visit China since the start of the pandemic, which was first detected there in 2019. China’s relations with Europe have deteriorated amid tensions over Taiwan, human rights issues and Beijing’s tacit support for Russia in its war on Ukraine. China has welcomed Scholz’s visit, saying it would “contribute to world peace, stability and growth.” But it received considerable pushback in Europe. Fears over Chinese interferenceScholz’s one-day visit to Beijing comes amid heightened fears in Europe over Chinese interference abroad. Wang suggested Europe could have the “best of both worlds” by playing a mediating role between Beijing and Washington.

Pfizer-BioNTech's updated booster shot generates a stronger immune response against the omicron subvariants BA.4 and BA.5 compared with the original Covid vaccine, the companies said in a release Friday. Pfizer's original vaccine formula, which was first administered to older adults in December 2020, was designed to target the original coronavirus strain. The updated booster shot is designed to target the original virus strain, as well as BA.4 and BA.5, in a single shot. Two independent studies posted online late last month suggested that the updated shots do not offer better protection against the new omicron subvariants than the original vaccines do. The new findings may hint that the updated booster is better than the original vaccine, but not by much, said John Moore, a professor of microbiology and immunology at Weill Cornell Medical College.

☆ China Agrees to Approve BioNTech's Covid-19 Vaccine for Foreigners, German Chancellor Says
▼ + stars: | 2022-11-04 | by ( Sha Hua | ) www.wsj.com time to read: 1 min

SINGAPORE—China agreed to approve BioNTech SE’s Covid-19 vaccines for foreign residents, German Chancellor Olaf Scholz said in Beijing Friday, in what would mark the first approval of an mRNA vaccine for Covid-19 for use in China. Mr. Scholz and Chinese leader Xi Jinping also discussed a pathway for approving the BioNTech vaccine for the broader population in China, Mr. Scholz said in a news conference, suggesting that regulators at the European Medicines Agency would be involved.

☆ China Agrees to Approve BioNTech's Covid-19 Vaccines for Foreigners, German Chancellor Says
▼ + stars: | 2022-11-04 | by ( Sha Hua | ) www.wsj.com time to read: 1 min

SINGAPORE—China agreed to approve BioNTech SE’s Covid-19 vaccines for foreign residents, German Chancellor Olaf Scholz said in Beijing Friday, in what would mark the first mRNA vaccine for Covid-19 approved for use in China. Mr. Scholz and Chinese leader Xi Jinping also discussed a pathway for approving the BioNTech Covid vaccine for the broader population in China, Mr. Scholz said in a news conference, suggesting that regulators at the European Medicines Agency would be involved.

☆ Jim Cramer on China's approval of BioNTech Covid vaccines for foreigners
▼ + stars: | 2022-11-04 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailJim Cramer on China's approval of BioNTech Covid vaccines for foreignersCramer explained how the news could affect the stock of companies that conduct business in China.

☆ Pfizer/BioNTech say updated Covid-19 booster generates 'substantially higher' protection against Omicron subvariants than original vaccin
▼ + stars: | 2022-11-04 | by ( Jen Christensen | ) edition.cnn.com time to read: +3 min

CNN —Pfizer and BioNTech said Friday that the immune responses against Omicron BA.4/BA.5 subvariants were “substantially higher” in people who got its new bivalent booster compared with people who received the companies’ original Covid-19 vaccine. The bivalent booster that targets the original coronavirus strain and the Omicron BA.4 and BA.5 subvariants became available in the US in early September. When someone gets any vaccine, it can take a few weeks to build up immunity and generate its full protection. The Omicron BA.5 subvariant had dominated US Covid-19 infections since July, but a mix of other Omicron subvariants have been gaining against it. So far, 26.3 million people age 5 and older in the United States have received updated Covid-19 boosters.

☆ Factbox: What are the new BQ.1 and BQ.1.1 coronavirus variants, and why it matters
▼ + stars: | 2022-11-04 | by ( Julie Steenhuysen | ) www.reuters.com time to read: +3 min

The following describes the new coronavirus subvariants and how they may impact people. WHAT ARE BQ.1 AND BQ.1.1? In early July, BA.5 became the dominant subvariant of the coronavirus circulating in the United States, but in October it started giving way to BQ.1 and BQ.1.1. A study of blood from three dozen adults showed the shot increased neutralizing antibodies against the BA.4/BA.5 Omicron subvariants by fourfold compared with the original shot after one month. read moreIt is not yet clear whether that will translate into higher protection against the BQ.1 and BQ.1.1 subvariants, but their close relationship to BA.5 may work in the booster's favor.

☆ New hope China may soften on Covid boosts our stocks most tied to world's No. 2 economy
▼ + stars: | 2022-11-04 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

After all, Chinese officials have not announced an official transition away from their very strict Covid policy. Nevertheless, the moves in certain stocks tied to China — including many owned by the Club — show the market is taking the vaccine policy change in stride. The cosmetics giant has a big China business and just a few days ago it cut its sales guidance partly due to China's Covid policy. The price move provided some support for oil stocks in Friday's volatile stock market. It's not immediately clear when expatriates in China could actually start getting a shot of the BioNTech-Pfizer Covid vaccine.

☆ Jim Cramer's week ahead: Get ready to 'pounce' when the market is oversold
▼ + stars: | 2022-11-04 | by ( Krystal Hur | ) www.cnbc.com time to read: +3 min

Monday: BioNTech, Take-Two InteractiveBioNTechQ3 2022 earnings release at 5 a.m. AMC EntertainmentQ3 2022 earnings release at 4:15 p.m. ETProjected loss: $1.14 per shareProjected revenue: $871 millionCramer said that his Charitable Trust is sticking with the stock. ETProjected loss: 29 cents per shareProjected revenue: $1.45 billionMatterportQ3 2022 earnings release after the close; conference call at 4:30 p.m. ToastQ3 2022 earnings release at 4:05 p.m.

☆ The Fed, earnings, jobs and China: How we think about this week's deluge of data
▼ + stars: | 2022-11-04 | by ( Zev Fima | ) www.cnbc.com time to read: +8 min

It is very premature, in my view, to think about or be talking about pausing our rate hikes. The news sent those stocks reliant on China for growth — Starbucks, Estee Lauder and Wynn Resorts, among many others — higher. Or bad news could just be bad news if weak data signals a recession ahead. And good news could be good news: for example, if China reopens and U.S. companies exposed to the region see a boost in demand. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ Scholz secures agreement allowing expats in China to use BioNTech COVID-19 vaccine
▼ + stars: | 2022-11-04 | by ( Andreas Rinke | ) www.reuters.com time to read: +1 min

BEIJING, Nov 4 (Reuters) - German Chancellor Olaf Scholz announced an agreement on Friday to let expatriates in China use the COVID-19 vaccine from Germany's BioNTech (22UAy.DE) and pressed for Beijing to allow the shot to be made freely available to Chinese citizens. On his first visit to China since becoming chancellor and the first by a G7 leader since the pandemic, Scholz said China and Germany had different approaches to fighting the virus but had a joint responsibility to eliminate it. The two countries "agreed on close cooperation in the fight against the pandemic," Scholz said in a briefing alongside the Chinese premier Li Keqiang. "This also includes an approval of the BioNTech vaccine for expatriates in China. I hope that the circle of eligible persons can soon be widened to a general free ability of the BioNTech vaccine," said Scholz.

☆ Midterms could be a positive catalyst for stocks as investors await next big inflation report
▼ + stars: | 2022-11-04 | by ( Patti Domm | In | ) www.cnbc.com time to read: +6 min

There are two big hurdles for markets in the week ahead - another potentially hot consumer inflation report and the Congressional midterm elections. "100% of the time, the S & P 500 has been up 12 months after the midterm election." Midterm rallies Stocks tend to gain in the final months of midterm election years, and strategists have been expecting the market to move higher. CFRA Chief Market Strategist Sam Stovall said even when interest rates are climbing, the midterm election has been a catalyst for stocks. He examined market performance in other midterm election years when interest rates were going up.

☆ What Cramer is watching Friday — Starbucks soars on China hope, jobs growth still strong
▼ + stars: | 2022-11-04 | by ( Jim Cramer | ) www.cnbc.com time to read: +5 min

Club holding Coterra Energy (CTRA): In Q3, nearly 500% year-on-year revenue growth to $2.52 billion. Cowen downgrades, sees acute pressure from worsening macro; management pulled 30% growth target. Warner Bros Discovery (WBD): $2.5 billion in cash, $50 billion in gross debt. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ Pfizer releases more data indicating omicron boosters are better than old Covid shots
▼ + stars: | 2022-11-04 | by ( Spencer Kimball | ) www.cnbc.com time to read: +4 min

Pfizer and BioNTech also found that people with and without prior Covid infections had a significant increase in their antibody levels after the omicron boosters. Pfizer and BioNTech released more human data Friday indicating the omicron BA.5 boosters perform better than the old Covid shots. Pfizer and BioNTech released the first human data in October showing the omicron boosters trigger a better immune response. They found the new boosters and the old shots performed about the same against omicron BA.5. The scientific community and public health officials are closely following data on the boosters because the FDA authorized them without direct human data.

Search resuls for: "BionTech"

25 mentions found